Immunomodulation by imiquimod in patients with high-risk primary melanoma

Journal of Investigative Dermatology

Volumn 132, Issue 1, 2012, Pages 163-169

  Narayan, Rupa ^a,b   Nguyen, Hong ^a,b   Bentow, Jason J ^a   Moy, Lauren ^a   Lee, Diana K ^a   Greger, Stephanie ^a,b   Haskell, Jacquelyn ^a   Vanchinathan, Veena ^a,b   Chang, Pei Lin ^a   Tsui, Shanli ^a   Konishi, Tamiko ^a   Comin Anduix, Begonya ^a,b   Dauphine, Christine ^a,b   Vargas, Hernan I ^a,b   Economou, James S ^a,b   Ribas, Antoni ^a,b   Bruhn, Kevin W ^a,b   Craft, Noah ^a,b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; IMIQUIMOD; PLACEBO; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR AGONIST;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CREAM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FLOW CYTOMETRY; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOCYTE COUNT; MELANOMA; PILOT STUDY; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SENTINEL LYMPH NODE; SKIN BIOPSY; TREATMENT OUTCOME;

EID: 84856080674     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2011.247     Document Type: Article

References (31)

1. Barnetson RS, Satchell A, Zhuang L et al. (2004) Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early infiltration by CD4 T cells and dendritic cells. Clin Exp Dermatol 29:639-43 (Pubitemid 39573657)
2. Buettiker UV, Yawalkar NY, Braathen LR et al. (2008) Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients. Arch Dermatol 144:943-5 (Pubitemid 352039751)
3. Comin-Anduix B, Gualberto A, Glaspy JA et al. (2006) Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays. Clin Cancer Res 12:107-16 (Pubitemid 43166183)
4. Comin-Anduix B, Lee Y, Jalil J et al. (2008) Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med 6:22
5. Cotter MA, McKenna JK, Bowen GM (2008) Treatment of lentigo maligna with imiquimod before staged excision. Dermatol Surg 34:147-51
6. Craft N, Bruhn KW, Nguyen BD et al. (2005) The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine. J Immunol 175:1983-90 (Pubitemid 41023106)
7. DeGiorgi V, Salvini C, Chiarugi A et al. (2009) In vivo characterization of the inflammatory infiltrate and apoptotic status in imiquimod-treated basal cell carcinoma. Int J Dermatol 48:312-21
8. Erickson C, Miller SJ (2010) Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery. Int J Dermatol 49:482-91
9. Gaspari A, Tyring SK, Rosen T (2009) Beyond a decade of 5% imiquimod topical therapy. J Drugs Dermatol 8:467-74
10. Gibson SJ, Lindh JM, Riter TR et al. (2002) Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 218:74-86 (Pubitemid 36027092)
11. Green DS, Dalgleish AG, Belonwu N et al. (2008) Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma. Br J Dermatol 159:606-14
12. Hemmi H, Kaisho T, Takeuchi O et al. (2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3:196-200 (Pubitemid 34141451)
13. Ito T, Amakawa R, Kaisho T et al. (2002) Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med 195:1507-12 (Pubitemid 34602828)
14. Lee JH, Torisu-Itakara H, Cochran AJ et al. (2005) Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res 11:107-12 (Pubitemid 40075784)
15. Ma F, Zhang J, Zhang J et al. (2010) The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice. Cell Mol Immunol 7:381-8
16. Molenkamp BG, van Leeuwen PA, Meijer S et al. (2007) Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin Cancer Res 13:2961-9 (Pubitemid 46849571)
17. Naylor MF, Crowson N, Kuwahara R et al. (2003) Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 149(Suppl 66):66-70
18. Oh DY, Taube S, Hamouda O et al. (2008) A functional toll-like receptor 8 variant is associated with HIV disease restriction. J Infect Dis 198:701-9
19. Ooi T, Barnetson RS, Zhuang L et al. (2006) Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial. Br J Dermatol 154:72-8 (Pubitemid 43381323)
20. Pinzon-Charry A, Maxwell T, Lopez JA (2005) Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol 83:451-61 (Pubitemid 41805745)
21. Powell AM, Robson AM, Russell-Jones R et al. (2009) Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up. Br J Dermatol 160:994-8
22. Prins RM, Craft N, Bruhn KW et al. (2006) The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol 176:157-64 (Pubitemid 43023259)
23. Rajpar SF, Marsden JR (2006) Imiquimod in the treatment of lentigo maligna. Br J Dermatol 155:653-6 (Pubitemid 44352542)
24. Schott E, Witt H, Neumann K et al. (2008) Association of TLR7 single nucleotide polymorphisms with chronic HCV-infection and response to interferon-a-based therapy. J Viral Hepat 15:71-8 (Pubitemid 350243584)
25. Shu S, Cochran AJ, Huang RR et al. (2006) Immune responses in the draining lymph nodes against cancer: implications for immunotherapy. Cancer Metastasis Rev 25:233-42 (Pubitemid 43886398)
26. Stanley MA (2002) Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 27:571-7 (Pubitemid 35463873)
27. Takeda K, Akira S (2004) TLR signaling pathways. Semin Immunol 16:3-9 (Pubitemid 38147427)
28. Torres A, Storey L, Anders M et al. (2007) Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream. J Transl Med 5:7
29. Urosevic M, Dummer R, Conrad C et al. (2005) Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 97:1143-53 (Pubitemid 41511214)
30. Vuylsteke RJ, Molenkamp BG, Gietema HA et al. (2004) Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma. Cancer Res 64:8456-60 (Pubitemid 39491787)
31. Yang Y, Huang CT, Huang X et al. (2004) Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 5:508-15 (Pubitemid 38660463)